Modality
Degrader
MOA
GLP-1ag
Target
CGRP
Pathway
Epigenetic
DMD
Development Pipeline
Preclinical
~Sep 2015
→ ~Dec 2016
Phase 1
Mar 2017
→ Oct 2029
Phase 1Current
NCT03541890
558 pts·DMD
2017-03→2029-10·Active
558 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-06-122mo awayPh1 Dose Esc· DMD
2029-10-283.6y awayPh2 Data· DMD
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1/2
Active
Catalysts
Ph1 Dose Esc
2026-06-12 · 2mo away
DMD
Ph2 Data
2029-10-28 · 3.6y away
DMD
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03541890 | Phase 1/2 | DMD | Active | 558 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| ARG-1250 | Argenx | Phase 2 | C5 | |
| LEG-9870 | Legend Biotech | Phase 1 | CGRP | |
| ASN-4879 | Ascendis Pharma | Phase 3 | CGRP |